setoperone has been researched along with Basal Ganglia Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM | 1 |
| Ceulemans, DL; Gelders, YG; Hoppenbrouwers, ML; Janssen, PA; Reyntjens, AJ | 1 |
1 trial(s) available for setoperone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome | 2007 |
1 other study(ies) available for setoperone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone.
Topics: Adult; Aged; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Pyrimidinones; Schizophrenia; Serotonin Antagonists | 1985 |